Adjuvant chemo plus CRT best in nasopharyngeal carcinoma

December 19, 2016

(HealthDay)—For nonmetastatic nasopharyngeal carcinoma, the addition of adjuvant chemotherapy (AC) to chemoradiotherapy (CRT) is associated with the highest survival benefit, according to research published online Dec. 5 in the Journal of Clinical Oncology.

Laureen Ribassin-Majed, Ph.D., from the Université Paris-Saclay, and colleagues compared available treatments using individual patient data from the Meta-Analysis of Chemotherapy in Nasopharynx Carcinoma database. They considered all randomized trials of radiotherapy (RT) with or without in nonmetastatic nasopharyngeal ; data were included from 20 trials and 5,144 patients.

The researchers found that the three treatments with the highest probability of benefit on overall survival were CRT followed by AC (CRT-AC), CRT, and followed by CRT (IC-CRT), with hazard ratios of 0.65 (95 percent confidence interval [CI], 0.56 to 0.75), 0.77 (95 percent CI, 0.64 to 0.92), and 0.81 (95 percent CI, 0.63 to 1.04), compared with RT alone. For CRT-AC versus CRT alone, the hazard ratios were 0.85 (95 percent CI, 0.68 to 1.05) for overall survival, 0.81 (95 percent CI, 0.66 to 0.98) for progression-free survival, 0.70 (95 percent CI, 0.48 to 1.02) for locoregional control, and 0.87 (95 percent CI, 0.61 to 1.25) for distant control (DC).

"The addition of AC to CRT achieved the highest survival benefit and consistent improvement for all end points," the authors write. "The addition of IC to CRT achieved the highest effect on DC."

Several authors disclosed financial ties to the pharmaceutical industry.

Explore further: Tailored, dense-dose chemotherapy for early breast cancer does not result in significant improvement

More information: Full Text

Related Stories

Hematologic markers predict nasopharyngeal cancer survival

September 22, 2015

(HealthDay)—Pretreatment neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) may be predictors for survival in nasopharyngeal carcinoma, according to a study published online Sept. 11 in Head & Neck.

Tasquinimod improves radiographic PFS in mCRPC

June 16, 2016

(HealthDay)—For chemotherapy-naive men with metastatic castration-resistant prostate cancer (mCRPC), tasquinimod is associated with improved radiographic progression-free survival (rPFS), according to a phase III study ...

Recommended for you

Ancient stress response provides clues to cancer resistance

April 25, 2017

Cancer is often able to craftily outwit the best techniques modern medicine has developed to treat it. In an attempt to understand and combat cancer's vaunted prowess, an unusual collaboration between physicists and a leading ...

Studying a catalyst for blood cancers

April 25, 2017

Imagine this scenario on a highway: A driver starts to make a sudden lane change but realizes his mistake and quickly veers back, too late. Other motorists have already reacted and, in some cases, collide. Meanwhile, the ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.